- Home
- BCSF vs AVBP Comparison
BCSF vs AVBP Comparison
Compare BCSF & AVBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCSF
- AVBP
- Stock Information
- Founded
- BCSF 2015
- AVBP 2021
- Country
- BCSF United States
- AVBP United States
- Employees
- BCSF N/A
- AVBP N/A
- Industry
- BCSF Finance/Investors Services
- AVBP
- Sector
- BCSF Finance
- AVBP
- Exchange
- BCSF Nasdaq
- AVBP NYSE
- Market Cap
- BCSF 978.9M
- AVBP 862.8M
- IPO Year
- BCSF 2018
- AVBP 2024
- Fundamental
- Price
- BCSF $15.28
- AVBP $21.18
- Analyst Decision
- BCSF Buy
- AVBP Strong Buy
- Analyst Count
- BCSF 2
- AVBP 8
- Target Price
- BCSF $16.50
- AVBP $38.38
- AVG Volume (30 Days)
- BCSF 259.4K
- AVBP 321.3K
- Earning Date
- BCSF 08-05-2025
- AVBP 08-13-2025
- Dividend Yield
- BCSF 10.99%
- AVBP N/A
- EPS Growth
- BCSF N/A
- AVBP N/A
- EPS
- BCSF 1.75
- AVBP N/A
- Revenue
- BCSF $284,993,000.00
- AVBP N/A
- Revenue This Year
- BCSF N/A
- AVBP $85.82
- Revenue Next Year
- BCSF N/A
- AVBP N/A
- P/E Ratio
- BCSF $8.74
- AVBP N/A
- Revenue Growth
- BCSF N/A
- AVBP N/A
- 52 Week Low
- BCSF $13.20
- AVBP $15.47
- 52 Week High
- BCSF $19.21
- AVBP $36.37
- Technical
- Relative Strength Index (RSI)
- BCSF 48.47
- AVBP 44.56
- Support Level
- BCSF $15.16
- AVBP $21.10
- Resistance Level
- BCSF $15.82
- AVBP $22.29
- Average True Range (ATR)
- BCSF 0.25
- AVBP 1.01
- MACD
- BCSF -0.00
- AVBP -0.03
- Stochastic Oscillator
- BCSF 33.33
- AVBP 33.78
About BCSF Bain Capital Specialty Finance Inc.
Bain Capital Specialty Finance Inc is an externally managed, closed-end, non-diversified management investment company. The company's objective is to provide risk-adjusted returns and current income to investors by investing predominantly in middle-market companies with between $10.0 million and $150.0 million in annual EBITDA. Its portfolio of investments includes First Lien Senior Secured Loan, Preferred Equity, Equity Interest, Warrants, and Second Lien Senior Secured Loan among others.
About AVBP ARRIVENT BIOPHARMA INC
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.